<DOC>
	<DOC>NCT01504906</DOC>
	<brief_summary>The purpose of this study is to assess the effect of Cyclosporine on the blood levels of Ticagrelor.</brief_summary>
	<brief_title>Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor</brief_title>
	<detailed_description>A Single-Center,Open-Label,Randomized,3-Treatment,3-Period Cross-Over Study to Investigate the Potential Effect of Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Ticagrelor and the Effect of Ticagrelor on the Pharmacokinetics, Safety, and Tolerability of Cyclosporine.</detailed_description>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Provision of signed and dated written informed consent prior to any studyspecific procedures Healthy male subjects aged 18 to 45 years (inclusive) with suitable veins for cannulation or repeated venipuncture History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs A history of hemophilia, von Willebrand's disease, lupus anticoagulant, or other diseases/syndromes that can either alter or increase the propensity for bleeding A personal history of vascular abnormalities including aneurysms; a personal history of severe hemorrhage, hematemesis, melena, hemoptysis, severe epistaxis, severe thrombocytopenia, intracranial hemorrhage, or rectal bleeding within 1 year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy male volunteers</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>Bioavailability (plasma AUC, Cmax, plasma AUC0-t, t1/2Î»z, tmax)</keyword>
</DOC>